Home/Filings/4/0001415889-25-006024
4//SEC Filing

RICHMOND TIMOTHY J. 4

Accession 0001415889-25-006024

CIK 0001551152other

Filed

Feb 27, 7:00 PM ET

Accepted

Feb 28, 5:00 PM ET

Size

19.4 KB

Accession

0001415889-25-006024

Insider Transaction Report

Form 4
Period: 2025-02-26
RICHMOND TIMOTHY J.
SVP, Human Resources
Transactions
  • Sale

    Common stock, $0.01 par value

    2025-02-26$202.92/sh13,073$2,652,77349,113 total
  • Sale

    Common stock, $0.01 par value

    2025-02-26$202.06/sh1,400$282,88450,591 total
  • Sale

    Common stock, $0.01 par value

    2025-02-26$203.64/sh1,526$310,75544,284 total
  • Sale

    Common stock, $0.01 par value

    2025-02-26$203.63/sh4,829$983,32944,284 total
  • Sale

    Common stock, $0.01 par value

    2025-02-26$202.93/sh4,781$970,20845,810 total
  • Exercise/Conversion

    Common stock, $0.01 par value

    2025-02-26$114.36/sh+22,210$2,539,93666,494 total
  • Sale

    Common stock, $0.01 par value

    2025-02-26$201.97/sh4,308$870,08762,186 total
  • Exercise/Conversion

    Option (Right to buy)

    2025-02-26$114.36/sh22,210$2,539,9360 total
    Exercise: $114.36From: 2019-02-15Exp: 2028-02-14Common Stock (22,210 underlying)
Footnotes (8)
  • [F1]This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on November 27, 2024.
  • [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.58 to $202.45, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.58 to $203.56, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F4]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.58 to $203.65, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F5]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.55 to $202.48, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F6]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.55 to $203.46, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F7]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $203.55 to $203.68, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F8]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

Issuer

AbbVie Inc.

CIK 0001551152

Entity typeother

Related Parties

1
  • filerCIK 0001563523

Filing Metadata

Form type
4
Filed
Feb 27, 7:00 PM ET
Accepted
Feb 28, 5:00 PM ET
Size
19.4 KB